XB-IMG-171210
Xenbase Image ID: 171210
|
Fig. S6. Specificity of Gli2 and Gli3 antibodies. (A) Western blot assays from wild-type (Control) or Gli3-targeted–morpholino-injected (Gli3-MO) embryos at
stage 20 (21.75 hpf) probed with antibody for Gli3 and H2B (loading control). Gli3-FL: Gli3 full length; Gli3-R: Gli3 repressor. Shown is a representative example.
(B and C) Western blot assays from wild-type or mGli2-GFP–expressing embryos at stage 13 (14.75 hpf) probed with antibody for Gli2 (goat, R&D Systems) and
H2B (loading control). Gli2-FL: Gli2 full length; Gli2-R: Gli2 repressor. Endogenous Gli2 is detectable (C) only when anti-Gli2 is incubated for ≥48 h and with
longer exposure times than for detecting the exogenously expressed mGli2-GFP (B). Shown are representative examples. (D) Two-cell-stage embryos were
unilaterally injected with Gli2-MO along with a dextran-Alexa fluor 647 conjugate (blue), grown until stage 20 (21.75 hpf), and then were processed for Gli2 [in
green, goat anti-Gli2 (R&D Systems); in red, mouse anti-Gli2 (Genetex)] immunostaining and nuclear labeling (DAPI, gray). Shown is a representative example
of a transverse immunostained section of the neural tube (outlined). (Scale bar: 30 μm.) Image published in: Belgacem YH and Borodinsky LN (2015) Copyright © 2015. Image reproduced with permission of the publisher and the copyright holder. This is an Open Access article distributed under the terms of the Creative Commons Attribution License.
Image source: Published Larger Image Printer Friendly View |